The renin-angiotensin system constitutes a major hormonal cascade regulating fluid and electrolyte balance and blood pressure (BP), the principal effector of which is angiotensin II (Ang II) (1). The vast majority of the physiological effects of Ang II are mediated by the subtype-1 (AT 1 ) angiotensin receptor; the function of the subtype-2 (AT 2 ) receptor remains to be determined (2). AT 2 receptors are present in the kidney and are upregulated by sodium depletion and Ang II (3, 4).
Introduction
The renin-angiotensin system constitutes a major hormonal cascade regulating fluid and electrolyte balance and blood pressure (BP), the principal effector of which is angiotensin II (Ang II) (1) . The vast majority of the physiological effects of Ang II are mediated by the subtype-1 (AT 1 ) angiotensin receptor; the function of the subtype-2 (AT 2 ) receptor remains to be determined (2) . AT 2 receptors are present in the kidney and are upregulated by sodium depletion and Ang II (3, 4) .
Ang II stimulates production of prostacyclin (PGI 2 ) and prostaglandin E 2 (PGE 2 ) (5). The angiotensin receptor subtype mediating renal prostanoid formation is largely unknown. We have shown previously in the rat kidney that the AT 1 receptor mediates Ang II-induced PGE 2 production and that pharmacological blockade of the AT 2 receptor potentiates Ang II-induced PGE 2 levels (6) . We also demonstrated that Ang II stimulates an increase in renal PGF 2α through an action at the AT 2 receptor (7).
This study was conducted to evaluate the role of the AT 2 receptor in prostaglandin metabolism and to investigate the mechanisms involving prostaglandins in maintaining normal BP. To address these issues, we used a novel microdialysis technique and mice with targeted disruption of the AT 2 receptor gene to monitor changes in 6-keto-PGF 1α (a stable hydrolysis product of PGI 2 ), PGE 2 , PGF 2α , and cAMP (the major second messenger of PGE 2 and PGI 2 ) in renal interstitial fluid (RIF) (5, 8) .
Methods
Targeted disruption of the mouse AT 2 receptor gene. This procedure was performed as described (9) . In brief, the coding region of embryonic stem cells (E14-1) in the third exon of the AT 2 receptor gene on the X chromosome was disrupted with a construct containing a neomycin-resistant expression cassette and herpes simplex virus thymidine-kinase expression cassette. The gene-disrupted cells were selected by G418 and ganciclovir, followed by Southern blot analysis to validate the desired gene disruption. Four targeted clones were obtained from 800 double-resistant colonies, 2 of which were injected into blastocysts derived from C57BL/6 mice, and the blastocysts were implanted into the uterus of pseudopregnant JCR mice. Of 34 chimeras, germ-line transmission occurred in 11 mice. Heterozygous female mice and wildtype (WT) male mice were mated to generate hemizygous male mice. Homozygous female mice were generated by mating heterozygous females with hemizygous males. The presence of a homozygous mutated AT 2 receptor gene was confirmed by Southern blot analysis.
Homozygous female AT 2 -null mice(agtr2 -/-) and their WT counterparts (agtr2 +/+ ) were generated from the littermates produced from the third backcross of heterozygous females (agtr2 +/-) to C57BL/6 males (agtr2 +/Y ), as follows. Heterozygous females (agtr2 +/-) and hemizygous males (agtr2 -/Y ) were crossed to obtain homozygous females (agtr2 -/-). From the same littermates, heterozygous females (agtr2 +/-) and WT males (agtr2 +/Y ) were crossed to obtain WT females (agtr2 +/+ ). Mice with the agtr2 -/-genotype were used as AT 2 -null mice. Those with the agtr2 +/+ genotypes were used as WT. The genotype of each individual mouse was confirmed by Southern blotting of DNA from the tail, as described (9). Our AT 2 -null mice were at the third backcross stage, which did not warrant the use of inbred C57BL/6 females as control. Therefore, we produced female agtr2 +/+ and agtr -/-mice by mating littermates produced from the third backcross.
In vivo microdialysis technique. For the determination of RIF autacoids, we constructed a microdialysis probe using a modification of a technique described previously (6, 7, 10) . Substances with a molecular mass greater than 10 kDa cannot cross into the dialysis probe. This molecular mass cutoff allows free passage of 6-keto-PGF 1α , PGE 2 , PGF 2α , and cAMP. The dead volume of the dialysis tubing and outflow tube was 3.6 µL. The microdialysis probe was sterilized by a gas sterilization method. The rate of flow of dialysate was maintained at 3 µL/min.
In vitro microdialysis. RIF prostaglandin levels generally parallel, but are more sensitive than, urine prostaglandin excretion. In vitro best recoveries for renal autacoids were observed with a perfusion rate of 3 µL/min, and were 81% for 6-keto-PGF 1α , 63% for PGE 2 , 60% for PGF 2α , and 84% for cAMP. We have demonstrated previously that negligible amounts of these substances stick to the polyethylene tubes (6) .
Animal preparation. Experiments were conducted in 25 homozygous and 25 WT mice 12-16 weeks old. Mice were anesthetized with 80 mg/kg ketamine (Fort Dodge Laboratories, Fort Dodge, Iowa, USA) and 8 mg/kg xylazine (Bayer Corp., Animal Health Division, Shawnee, Kansas, USA), both administered intramuscularly. The right and left kidneys were exposed by a midline abdominal incision. Microdialysis probes were inserted into the kidneys of both the homozygous and WT mice. The renal capsule was penetrated with a 31-gauge needle that was tunneled into the outer renal cortex about 1 mm from the outer renal surface for 0.3 cm before it exited by penetrating the capsule again. The tip of the needle was inserted into the end of the dialysis probe, and the needle was pulled through with the dialysis tube until the dialysis fiber was situated in the renal cortex. The inflow and outflow tubes of the dialysis probes were tunneled subcutaneously through a bevel-tipped stainless steel tube and exteriorized near the intrascapular region. The exterior ends of the tubes were secured in place by suturing them to the skin at the exit site. The exteriorized portions of the tubes were placed in a stainless steel spring (to prevent the mice from damaging them).
To infuse Ang II or vehicle, an osmotic minipump (model 1007D; Alza Corp., Palo Alto, California, USA) was implanted in the subcutaneous space in the interscapular area, and Ang II or vehicle was infused subcutaneously. No tissue necrosis was observed with Ang II infusion.
Mice were housed under controlled conditions (temperature 21 ± 1°C, humidity 60 ± 10%, lighting for 8-20 hours). Experiments were initiated at the same time each day to avoid diurnal variation of the measured body weight, systolic blood pressure (SBP), or RIF mediators. For collection of RIF, the inflow tube was connected to a gas-tight syringe that was filled with lactated Ringer's solution and perfused at 3 µL/min. The effluent was collected from the outflow tube for 30-minute sample periods in nonheparinized plastic tubes and stored at −80°C until measured for PGE 2 , PGF 2α , and cAMP. The known PGI 2 -and cAMP-generating and -degrading enzymes (mol wt = 34,000-150,000) do not cross the dialysis membrane because of their size. A histological examination of the renal tissue 6 weeks after insertion of the dialysis probe did not show any fibrosis or scarring (6) .
Urine was collected in special metabolic cages designed for individual mice. Urine was collected by a closed system that prevents evaporation or fecal contamination.
BP measurements. SBP was measured in the tail artery in homozygous and WT mice under restraint using an automated sphygmomanometer (model 679; IITC/Life Sciences Instruments, Woodland, California, USA) after a 7-day training period. BPs were recorded at 10-minute intervals for 30 minutes each morning during the study period (model 179 Apollo Recorder; Life Sciences Instruments), and values were averaged each day.
Analytical methods. Urinary sodium concentrations were measured with a Nova analyzer (Nova Biomedical, Waltham, Massachusetts, USA). PGE 2 , PGF 2α , and 6-keto-PGF 1α were measured by an enzymatic immunoassay (Cayman Chemical, Ann Arbor, Michigan, USA). The sensitivities and specificities of the assay for PGE 2 were 114 pg/mL and 100%, respectively; for PGF 2α , 14.2 pg/mL and 100%, respectively; and for 6-keto-PGF 1α , 11 pg/mL and 100%, respectively. The intra-and interassay coefficients of variation were less than 10% for each assay. cAMP was measured by enzyme immunoassay (Cayman Chemical) with an assay sensitivity of 20 fmol and specificity of 100%.
Effects of dietary sodium restriction on BP, sodium excretion, and RIF mediators. Homozygous (n = 10) and WT (n = 10) mice were placed in metabolic cages. Baseline BPs and heart rates were measured, and a baseline 24-hour urine collection was obtained for calculation of urine flow rate (V) and sodium excretion (U Na V). RIF samples were obtained for PGE 2 , PGF 2α , 6-keto-PGF 1α , and cAMP (experimental day 1) while mice were consuming a normal sodium diet (0.28% NaCl; BioServe Biotechnologies Inc., Frenchtown, New Jersey, USA). After experimental day 1, mice were placed on a low-sodium diet (0.04% NaCl) for 7 days. On the seventh day of low sodium intake, the study was repeated as already outlined here.
Effects of chronic Ang II infusion on BP, sodium excretion, and RIF autacoids. Homozygous (n = 10) and WT (n = 10) mice were placed in metabolic cages on normal sodium intake for 10 days. On experimental day 1, a baseline 24-hour urine collection was obtained for calculation of V and U Na V, and RIF samples for PGE 2 , PGF 2α , 6-keto-PGF 1α , and cAMP were obtained. At 0800 hours on study experimental day 2, a subcutaneous infusion of Ang II (4 pmol/kg/min) or vehicle was initiated and continued for 6 days (experimental days 2-7) using the osmotic minipump. BP, heart rate, V, and U Na V were monitored daily. On experimental day 7, RIF samples for autacoids were again obtained. At 0800 hours on experimental day 8, the infusion of Ang II was discontinued, and a vehicle infusion was substituted for 4 additional days (experimental days 8-11) while BP, HR, V, and U Na V measurements were continued.
Effects of indomethacin on BP, sodium excretion, and RIF mediators. To determine whether the absence of a large rise in baseline BP in AT 2 -null mice was due to an increase in renal PGE 2 , we administered indomethacin, a cyclooxygenase inhibitor, to homozygous (n = 10) and WT (n = 10) mice during normal sodium intake. After baseline RIF measurements on control day 0, as already described here, mice were given indomethacin (5 mg/kg/d) or vehicle intraperitoneally for 14 experimental days. BP was measured daily. At the end of this time, the measurements were repeated. No gastrointestinal toxicity due to indomethacin was observed.
Effects of AT 1 receptor blockade on RIF autacoids in AT 2 -null mice. To determine the mechanism of the increase in renal PGE 2 , 6-keto-PGF 1α , and cAMP in AT 2 -null mice, we administered a bolus dose of 10 mg/kg of the AT 1 receptor antagonist losartan via tail vein to conscious AT 2 -null mice (n = 5) with an indwelling renal microdialysis probe. Two hours later, RIF was obtained over a 1-hour collection period for PGE 2 , 6-keto-PGF 1α , and cAMP.
Effects of AT 2 receptor blockade on RIF autacoids in WT.
To confirm the mechanism of the reduction in PGF 2α in AT 2 -null mice, we administered the AT 2 receptor antagonist PD123319 (PD; 50 µg/kg/min) to WT mice (n = 5) by osmotic minipump for 5 consecutive days. RIF samples were collected on day 1 after initiation of a vehicle infusion or infusion of PD with the animals on a normal sodium diet (0.31% sodium), after which they were placed on a low-sodium diet (0.08% sodium) for 4 days during vehicle or PD infusion. RIF PGE 2 and PGF 2α were again measured on day 5 of the low-sodium diet in the presence of PD or vehicle.
Statistical analysis. Comparisons between normal and low sodium intake, and between Ang II or indomethacin and vehicle, were estimated by repeatedmeasures ANOVA, using the General Linear Models procedure of the Statistical Analysis System (Virginia Polytechnic and State University, Blacksburg, Virginia, USA). Multiple comparisons of individual pairs of effect means were conducted by least-square means pooled variance. Data are expressed as mean ± SEM. Statistical significance was identified at P < 0.05.
Results
BP, V, and U Na V responses to dietary sodium restriction and Ang II infusion. BP was slightly but significantly higher in AT 2 -null mice (n = 10) than in WT mice (n = 10) at baseline (Table 1) . Sodium restriction did not alter BP in either AT 2 -null or WT mice. Ang II infusion increased BP significantly in AT 2 -null mice but not in WT mice. V and U Na V were similar in AT 2 -null and WT mice. In response to sodium restriction, V was unchanged but U Na V was significantly reduced in both WT and AT 2 -null mice. Ang II infusion decreased V and U Na V significantly in AT 2 -null mice but not in WT mice.
RIF PGE 2 , PGF 2α , 6-keto-PGF 1α , and cAMP responses to dietary sodium restriction. Figure 1a depicts PGE 2 levels during normal sodium intake and after 7 days of dietary sodium restriction. During normal sodium intake, PGE 2 was significantly increased in AT 2 -null mice compared with WT mice. Dietary sodium restriction increased PGE 2 both in AT 2 -null and WT mice. In sodium-restricted animals, PGE 2 levels in AT 2 -null mice were more than 2-fold higher than in WT mice. Figure 1b demonstrates PGF 2α levels. PGF 2α was significantly lower in AT 2 -null mice than in WT mice during normal sodium intake. Dietary sodium restriction increased PGF 2α in WT mice but significantly decreased PGF 2α in AT 2 -null mice. In sodiumrestricted animals, PGF 2α levels were more than 10-fold higher in WT mice than in AT 2 -null mice. Figure 1c shows RIF levels of 6-keto-PGF 1α . Basal levels of 6-keto-PGF 1α were higher in AT 2 -null mice than in WT mice. In both WT and AT 2 -null mice, 6-keto-PGF 1α increased significantly in response to sodium restriction. There was no significant difference in the incremental change to sodium restriction between WT and AT 2 -null mice. AT 2 -null mice had approximately 26-fold higher cAMP levels (Figure 1d) than did WT mice during normal sodium intake. Low sodium intake resulted in no significant change in cAMP in either AT 2 A =P < 0.001 from WT. B P < 0.0002 from control. C P < 0.0001 from control. levels (Figure 2a ) than did WT mice during vehicle infusion. Ang II infusion increased PGE 2 in both WT and AT 2 -null mice, the increase being significantly greater in WT mice. After Ang II infusion, AT 2 -null mice had PGE 2 levels similar to those in WT mice. AT 2 -null mice had lower PGF 2α levels (Figure 2b ) than did WT mice during vehicle infusion. In WT mice, PGF 2α was increased approximately 4-fold by chronic Ang II infusion, whereas in AT 2 -null mice, there was no significant change in PGF 2α levels in response to Ang II. Responses of 6-keto-PGF 1α to exogenous Ang II are shown in Figure 2c . Basal control levels of 6-keto-PGF 1α were higher in AT 2 -null mice than in WT mice. Both WT and AT 2 -null mice had significant increases in 6-keto-PGF 1α in response to Ang II, and there was no difference in these responses between the two. cAMP values (Figure 2d ) were significantly higher in AT 2 -null mice than in WT mice, both basally and in response to Ang II. Ang II did not significantly alter cAMP in either WT or AT 2 -null mice.
BP responses to indomethacin. In AT 2 -null mice, BP increased progressively and dramatically well into the hypertensive range in response to intraperitoneally administered indomethacin (5 mg/kg/d) ( Figure 3 ).
There was no change in BP on any day of the vehicle time control. BP before vehicle administration was 102 ± 5 mmHg and was 103 ± 2 mmHg after 14 days of vehicle administration. There was no change in BP in WT mice in response to indomethacin (Figure 3) .
RIF PGE 2 , PGF 2α , and cAMP responses to chronic indomethacin administration. PGE 2 (Figure 4a ) values were about 3.5-fold higher in AT 2 -null mice than in WT mice on day 0 before indomethacin administration. In response to 14 consecutive days of indomethacin administration, PGE 2 was significantly decreased in both WT and AT 2 -null mice. PGE 2 values were not significantly different in WT and AT 2 -null mice after 14 days of indomethacin administration. PGF 2α levels ( Figure 4b ) were more than 3-fold lower in AT 2 -null mice than in WT mice at baseline. Indomethacin lowered PGF 2α both in WT and AT 2 -null mice. In indomethacin-treated animals, PGF 2α was significantly lower in AT 2 -null mice than in WT mice. Indomethacin decreased 6-keto-PGF 1α levels significantly in both WT and AT 2 -null mice, such that levels were not significantly different between the two (Figure 4c ). cAMP levels (Figure 4d ) in WT mice were low and were unchanged by indomethacin. In AT 2 -null mice, cAMP levels were relatively high at baseline and were markedly reduced. Figure 5 , control values for PGE 2 , 6-keto-PGF 1α , and cAMP in AT 2 -null mice were 39 ± 7, 39 ± 4, and 16 ± 3 pg/min, respectively. In response to losartan, PGE 2 decreased (P < 0.0001) to less than one third of control values and to a value similar to that of WT mice. Similarly, 6-keto-PGF 1α decreased to about 40% of control values (P < 0.0001). Losartan caused a parallel reduction of cAMP (P < 0.0001) to values similar to those of WT mice.
RIF PGE 2 , 6-keto-PGF 1α , and cAMP responses to AT 1 receptor blockade in AT 2 -null mice. As shown in
RIF PGE 2 and PGF 2α responses to AT 2 receptor blockade in sodium-restricted WT mice. Figure 6 depicts the incremental increase in PGE 2 and PGF 2α in response to dietary sodium restriction for 5 days in the presence or absence of continuous intravenous infusion of PD. Sodium restriction increased both PGE 2 and PGF 2α in mice receiving only vehicle infusion. AT 2 receptor blockade with PD further increased PGE 2 but decreased the PGF 2α response to sodium restriction (both P < 0.01).
Discussion
This study demonstrates that Ang II acts at the AT 1 receptor to stimulate both PGI 2 and PGE 2 production in the kidney. PGE 2 is the major renal prostanoid and has substantially greater vasodilator potency than PGI 2 in the rat kidney (5). PGI 2 is the major metabolite of arachidonic acid in vascular endothelial cells (6) . The baseline increase in renal PGE 2 and 6-keto-PGF 1α in AT 2 -null mice is the result of interruption of receptor cross-talk and the presence of "unopposed" AT 1 receptors in these mice, as AT 1 receptor blockade normalized PGE 2 and 6-keto-PGF 1α in AT 2 -null mice. These observations suggest that the AT 2 receptor has a tonic inhibitory action on the production of PGI 2 and PGE 2 , which is driven by the AT 1 receptor.
It is generally appreciated that Ang II can stimulate PGI 2 and PGE 2 production in nonrenal tissues. Studies
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The Journal of Clinical Investigation | July 1999 | Volume 104 | Number 2 using isolated vascular smooth muscle cells and isolated perfused heart preparations have demonstrated that Ang II stimulates PGI 2 release through an interaction at AT 1 receptors (11) (12) (13) (14) (15) . However, the angiotensin subtype receptor responsible for renal PGE 2 and PGI 2 formation has not been studied systematically. The results of the present study show that both renal PGI 2 and PGE 2 production are stimulated in parallel by either endogenous (sodium restriction) or exogenous Ang II. PGI 2 and PGE 2 are both formed from the precursor PGH 2 , which is a product of cyclooxygenase action on its substrate, arachidonic acid. PGF 2α , another major renal prostanoid, can also be formed directly from PGH 2 or, alternatively, by conversion from PGE 2 through the action of PGE 2 9-ketoreductase (5). Prostaglandins are paracrine or autocrine substances, acting locally in the tissues in which they are formed (5). Because of their rapid degradation on passage across the lungs, these substances are not detectable in appreciable quantities in the circulation. However, prostanoids can be assayed and changes monitored in RIF with a high degree of sensitivity (6) . PGE 2 and PGF 2α are produced in renal interstitial and collecting duct cells and in the endothelium of vasa recta, and they participate in the regulation of renal function (16, 17) . The production of these autacoids is augmented by pressor hormones, including Ang II via stimulation of phospholipase A 2 , to form arachidonic acid substrate from membrane phospholipids (5, 18) . Ang II stimulates the endothelial release of arachidonic acid metabolites (19) (20) (21) . We have shown previously in the rat that Ang II stimulates renal PGE 2 production through the AT 1 receptor (6). Our present results are consistent with earlier observations in the normal rat kidney that conversion of PGE 2 to PGF 2α by 9-ketoreductase is enhanced by sodium depletion (22, 23) .
An important finding of the present study is that Ang II acts at the AT 2 receptor to stimulate PGF 2α , probably by conversion from PGE 2 . At baseline, mice lacking the AT 2 receptor had increased RIF levels of PGE 2 and low levels of PGF 2α . In WT mice, both sodium restriction (endogenous Ang II) and chronic infusion of a small quantity of exogenous Ang II increased 6-keto-PGF 1α, PGE 2 , and PGF 2α . Similarly, in AT 2 -null mice, sodium restriction and chronic Ang II infusion increased 6-keto-PGF 1α and PGE 2 . In marked contrast to WT mice, however, in AT 2 -null mice, both exogenous and endogenous Ang II failed to increase PGF 2α . These results were confirmed by experiments showing that sodium restriction increased PGE 2 , PGI 2 , and PGF 2α , and by separate experiments showing that AT 2 receptor blockade with PD blocked the increase in PGE 2 in WT mice. Our results underscore the physiological importance of the AT 2 receptor in the formation of PGF 2α , most likely through conversion from PGE 2 by 9-ketoreductase. Our data, however, do not permit determination of the effects, if any, of the AT 2 receptor on PGH 2 metabolism. Our data demonstrate that the increase in basal PGE 2 in AT 2 -null mice is largely related to absence of tonic inhibition of the AT 2 receptor on AT 1 receptor-mediated PGE 2 production.
The interaction between the renin-angiotensin system and renal eicosanoids is fundamental to the regulation of body fluid and sodium homeostasis (8) . PGI 2 and PGE 2 stimulate, whereas PGF 2α inhibits, renin secretion (24) . AT 2 receptor-mediated stimulation of PGF 2α formation, and its inhibitory effect on renin secretion, is in agreement with recent findings that the AT 2 receptor may indirectly mediate vasodilation (9) . PGE 2 inhibits sodium reabsorption in the cortical and medullary collecting ducts and leads to natriuresis (25) . Sodium depletion increases renal Ang II formation (26) , and it is likely that the resulting increase in conversion of PGE 2 to PGF 2α is related to increased Ang II formation and stimulation of the AT 2 receptor. The decrease in sodium excretion during sodium restriction is likely mediated by AT 1 receptors in renal tubule cells in both WT and AT 2 -null mice.
The tonic inhibitory action of the AT 2 receptor on AT 1 receptor-mediated PGI 2 and PGE 2 production may be due to several possible factors. (a) Nitric oxide, which is increased by AT 2 receptors, has been described to inhibit cyclooxygenase under some conditions (27, 28) . (b) cGMP, also increased by AT 2 receptors, may affect prostaglandin metabolism (28) . (c) Bradykinin, also increased by AT 2 receptors, can stimulate the production of nitric oxide and eicosanoids in the intact kidney (29) . (d) The AT 2 receptor may stimulate epoxide production through the cytochrome P 450 system, which may compete with arachidonic acid for metabolism by cyclooxygenase, resulting in inhibition of PGI 2 and PGE 2 formation (30, 31) . These possibilities will need to be resolved in future studies.
PGF 2α , the product of PGE 2 metabolism by 9-ketoreductase, binds mainly to the recently cloned FP receptor, resulting in a rise in intracellular calcium (32) . The FP receptor is thought to mediate vasoconstriction. PGF 2α also can bind to EP 1 and EP 3 receptors, both of which also mediate vasoconstriction (32) . In AT 2 -null mice, the decrease in PGF 2α may contribute to the absence of hypertension by reducing peripheral and/or renal vasoconstriction. PGE 2 has been shown to stimulate adenylyl cyclase via the EP 2 and EP 4 receptors with the generation of cAMP, which acts as its second messenger (8, 32) . These 2 receptors mediate vascular smooth muscle relaxation. cAMP is extruded from target cells by a prostanoid-sensitive membrane transporter and can be measured in the RIF. Our data demonstrate that cAMP levels were high in AT 2 -null mice (PGE 2 and PGI 2 levels also were elevated) compared with WT mice. An unanticipated finding was the failure of cAMP to increase in WT mice in response to sodium restriction or Ang II in proportion to the increase in PGE 2 . The parallel reduction of PGE 2 , 6-keto-PGF 1α , and cAMP by indomethacin suggests, however, that PGE 2 and/or PGI 2 are very likely responsible for elevated cAMP in AT 2 -null mice. Failure of cAMP to increase substantially in response to sodium restriction or Ang II in AT 2 -null mice may indicate maximum stimulation of cAMP production in the basal state.
Both PGE 2 and PGI 2 are vasodilators, and excessive vasodilator prostanoid accumulation in the absence of the AT 2 receptor may account for the absence of hypertension in this model. To test this hypothesis, we administered the cyclooxygenase inhibitor indomethacin and monitored BP. In response to indomethacin, which decreased renal 6-keto-PGF 1α , PGE 2 , and PGF 2α to low levels, BP steadily rose into the hypertensive range. These results suggest that increased PGI 2 and PGE 2 in AT 2 -null mice prevented the increase in BP that otherwise would have occurred, most likely owing to a reduction of other vasodilators such as bradykinin and/or nitric oxide, which are stimulated via the AT 2 receptor (6). It is also possible that in addition to decreasing vasodilator prostanoid production, indomethacin may have selectively inhibited vasodilator prostanoid signal transduction in target cells, as has been demonstrated in the cerebral microcirculation (33) . Therefore, the action of indomethacin to increase BP could be related to inhibition of both vasodilator prostanoid synthesis and action.
There are several limitations to the present study. (a) We were unable to measure plasma renin activity or Ang II concentrations because volume depletion might have
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The altered RIF autacoid levels. (b) Although we were able to monitor PGE 2 and PGF 2α levels, we were not able to measure the activity of PGE 2 9-ketoreductase directly. (c) Indomethacin has been reported to inhibit enzyme systems and cell signaling processes other than cyclooxygenase activity, including cAMP-and cGMP-phosphodiesterases, cAMP-dependent protein kinases and endogenous phosphorylation, active Ca 2+ transport, and adenosine uptake (33) . However, none of these potential actions of indomethacin could account for the ability of indomethacin to raise systemic BP or to decrease prostanoid or cAMP levels.
In summary, we have demonstrated that absence of the AT 2 receptor results in increased PGI 2 and PGE 2 and decreased PGF 2α levels in the kidney, both basally and in response to Ang II. These findings establish a physiological role of the AT 2 receptor in renal prostanoid production and metabolism. We also demonstrated that the renal vasodilator prostanoids PGE 2 and PGI 2 are stimulated via the AT 1 receptor, providing counterregulatory vasodilation in opposition to the vasoconstrictor action of Ang II. Most importantly, we demonstrated that in the absence of the AT 2 receptor, increased levels of these vasodilator prostanoids prevent the development of hypertension. 
Figure 6
Incremental increase in RIF PGE2 (a) and PGF2α (b) in WT mice (n = 5) in response to 5 days of dietary sodium restriction in the presence or absence of the AT2 receptor antagonist PD123319 (PD; 50 µg/kg/min). *P < 0.001 vs. vehicle control.
